Main Uses of Prostap

Prostap is a hormonal therapy medication used to manage conditions that are sensitive to sex hormones, specifically testosterone in men and oestrogen in women. It belongs to a group of medicines known as gonadorelin analogues (GnRH analogues).

Prostate Cancer

In men, Prostap is primarily used in the management of advanced prostate cancer. Most prostate cancer cells rely on testosterone to grow and divide. By reducing the production of testosterone from the testes to very low levels—often referred to as castrate levels—the medication can help to shrink the tumour or slow its progression. It may be used as a standalone treatment or in combination with other therapies.

Endometriosis

In women, Prostap is used to treat endometriosis, a condition where tissue similar to the lining of the womb grows in other parts of the body. This tissue responds to the menstrual cycle and can cause significant pain and inflammation. By lowering oestrogen levels, the medication suppresses the activity of this displaced tissue, providing relief from symptoms such as pelvic pain and painful periods.

Uterine Fibroids

Prostap is also used to treat uterine fibroids, which are non-cancerous growths in the wall of the uterus. The medication helps to shrink the size of the fibroids by reducing oestrogen levels. This is often done to alleviate symptoms like heavy menstrual bleeding or to reduce the size of the growths prior to surgical removal.

Early Puberty

In some instances, Prostap is used in children to treat precocious puberty (early-onset puberty). It works by temporarily pausing the hormonal signals that trigger the development of secondary sexual characteristics, allowing for more appropriate physical and emotional development over time.

Benefits of Treatment

Symptom Management

The primary benefit of Prostap across all indications is the management of symptoms driven by hormonal activity. This includes the reduction of bone pain in advanced prostate cancer, the alleviation of chronic pelvic pain in endometriosis, and the reduction of heavy blood loss associated with fibroids.

Disease Control

For patients with hormone-sensitive prostate cancer, the medication serves as a systemic treatment to control the spread of the disease. In gynaecological conditions, it can provide a period of hormonal suppression that allows the body to recover, often improving quality of life and potentially simplifying future surgical interventions.

Prostap (leuprorelin acetate) is a synthetic hormone-like medicine primarily indicated for treating prostate cancer in men and conditions like endometriosis and uterine fibroids in women. It may also be used in the management of central precocious puberty in children.

---

Who Can Use Prostap

Patient Group	Indication
Adult Men	Advanced prostate cancer.
Adult Women	Endometriosis, uterine fibroids (pre-operative or therapeutic).
Children	Central precocious puberty.

---

Who Should Not Use Prostap (Contraindications)

Prostap is contraindicated and should not be used by individuals with a known hypersensitivity or allergy to leuprorelin, any other gonadotropin-releasing hormone (GnRH) agonist, or any of the inactive ingredients.

Women who are pregnant or breastfeeding must not use this medication. Furthermore, it is not indicated for women with undiagnosed abnormal vaginal bleeding. Caution and medical consultation are also required for men with spinal cord compression or urinary tract obstruction due to potential exacerbation during initial treatment.

Prostap Interactions with other medicines and products

This section summarizes the officially documented interactions for Prostap (leuprorelin acetate) based strictly on governmental regulatory prescribing information, such as the Summary of Product Characteristics (SmPC) and the U.S. Food and Drug Administration (FDA) Prescribing Information.

Documented Interaction Patterns

The most significant interactions involve pharmacodynamic effects (affecting the body’s response) rather than changes in drug metabolism.

Interaction Type	Interacting Products	Regulatory Classification
Cardiac Conduction	Medicines that prolong the QT interval, such as certain Class IA and Class III Antiarrhythmics (e.g., Quinidine, Sotalol).	Use with Caution (especially in men receiving androgen deprivation therapy).
Hormonal Axis	Aromatase Inhibitors (e.g., Exemestane)	Contraindicated if initiated before adequate ovarian suppression with leuprorelin is confirmed.
Metabolic	None documented. Leuprorelin is degraded by peptidases, so interactions involving the CYP-450 enzyme system are not expected.	No Significant Interaction

Timing and Procedural Restrictions

For co-administration with Aromatase Inhibitors, there is a mandatory timing constraint: treatment with leuprorelin must be initiated at least 6–8 weeks before the Aromatase Inhibitor is started. This procedural requirement ensures the hormonal axis is suppressed prior to combining the agents.

How Prostap Works

Leuprorelin acetate is a gonadotrophin-releasing hormone (GnRH) agonist that modulates the hypothalamic-pituitary-gonadal (HPG) axis. The mechanism operates in two distinct phases.

Initially, the compound interacts with GnRH receptors located on the pituitary gland, functioning as an agonist. This initial binding and stimulation triggers the transient release of pituitary gonadotrophins, Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH), which results in a temporary elevation of sex steroid levels.

With continuous, non-pulsatile exposure, this sustained agonist presence leads to the desensitisation and downregulation of the pituitary GnRH receptors. This mechanistic cascade modifies the normal endocrine signaling sequences of the HPG axis. The subsequent physiological effect is a maintained suppression of LH and FSH secretion from the pituitary, a response also known as pharmacological hypophysectomy.

This reduction in pituitary hormones causes a substantial decrease in the downstream production and circulating concentrations of sex steroids, including testosterone and estrogen/estradiol. This system-level modulation influences pathway activity driven by these mediators, resulting in suppressed hormonal concentrations.

Prostap (leuprorelin acetate) is a prolonged-release suspension for injection that is typically administered by a healthcare professional, such as a doctor or nurse. It is available in various formulations, which dictate the frequency of administration.

Administration Details

Prostap is administered as an injection either:

• Subcutaneously (SC): Under the skin, often in the abdomen, thigh, or upper arm. This route is commonly used for both 1-month and 3-month formulations in prostate cancer and central precocious puberty.
• Intramuscularly (IM): Into the muscle, which may be an option for some 1-month and 3-month doses used for endometriosis and prostate cancer.

The specific injection site should be varied periodically (rotated) to prevent irritation or damage to the tissue. The drug must be used immediately after mixing as the suspension settles quickly.

Dosing Frequency

The frequency of the injection depends on the specific product (e.g., Prostap SR, Prostap 3) and the condition being treated:

Condition	Typical Frequency	Formulation (Example)
Prostate Cancer	Every month or every 3 months	3.75 mg or 11.25 mg
Endometriosis	Every month or every 3 months	3.75 mg or 11.25 mg
Central Precocious Puberty	Every month or every 3 months	Weight-based dosage

For endometriosis, treatment is typically initiated during the first five days of the menstrual cycle and is generally limited to a period of up to six months.

It is critical to adhere to the prescribed dosing schedule. If an injection appointment is missed, contact your healthcare provider immediately to receive the next dose as soon as possible.

Research Evidence / Overview of Studies for Prostap

This summary describes the types of clinical studies and research that have examined Prostap (leuprorelin) across its main therapeutic areas. It outlines what researchers have monitored and what findings have been described, while emphasizing that the evidence reflects group patterns and does not guarantee individual results.

---

Evidence for Use in Hormone-Dependent Cancers: Prostate and Breast Cancer

Prostap has been well-studied in the context of advanced prostate cancer, involving large-scale Randomized Controlled Trials (RCTs) and long-term observational studies. These studies were used in research exploring how patients fared over time, focusing on outcomes related to survival, tracking disease progression, and monitoring shifts in key biomarkers. The populations studied included adult men at various stages of the disease, such as advanced, metastatic, or high-risk localized cancer, including studies on older adults.

Studies monitored patterns related to changes in testosterone levels into the castration range during the study interval. Research describes observed patterns in long-term survival and tracked the evolution of a marker called Prostate-Specific Antigen (PSA) over many years of follow-up. This evidence contributes to the broader evidence landscape for established treatment protocols.

Similarly, Prostap was evaluated in studies of hormone-sensitive breast cancer in pre-menopausal women as part of combination regimens. These trials monitored outcomes related to recurrence prevention and survival metrics. Findings describe measured hormonal shifts in the study populations, but as this drug is usually applied with other therapies, research describes the observed effects within that combined approach.

---

Evidence for Use in Symptomatic Gynecological Conditions

Research exploring the use of Prostap in endometriosis and uterine fibroids has primarily utilized short-term Randomized Controlled Trials and clinical studies.

For symptomatic endometriosis, research examined how symptoms evolved in the observed populations, specifically monitoring outcomes related to physical discomfort and tracking the status of endometrial implants. Studies were conducted during periods of increased symptom activity in adult women of reproductive age. Research monitored fluctuations in pain symptom scores and measured estrogen levels. However, the treatment durations in most pivotal studies were generally limited to a few months. This means there is limited information for long-term outcomes regarding the recurrence of pain and disease status after treatment is stopped.

In uterine fibroids, studies monitored outcomes reflecting daily functioning or activity level, such as the extent of menstrual blood loss and changes in the size or volume of the fibroids. Research exploring short-term symptom changes, typically focused on pre-operative settings. Research highlights patterns measured during the study period related to both size and bleeding intensity. However, the evidence base mainly reflects short-term use, and data for certain groups remain insufficient regarding the long-term patterns of symptom recurrence for those who do not undergo subsequent surgery.

Key Studies & References

1. NICE Guideline NG176: Endometriosis: diagnosis and management

Common questions about Prostap (FAQ)

Q: Is Prostap the same as Zoladex or other similar injections?

A: Prostap contains the active ingredient leuprorelin acetate, which is classified as a Gonadotropin-Releasing Hormone (GnRH) analogue. While other injections, like Zoladex, belong to the same pharmacological class and have a similar action, they contain different specific active ingredients.

Q: Does Prostap commonly cause weight gain, and what is the reason for this?

A: Official regulatory documents list weight gain as a very common side effect reported in men using Prostap. For women, the product information indicates that weight changes may occur less frequently. The official regulatory documents do not specify the physiological reason or exact mechanism behind this effect.

Q: Is hair loss a common side effect of Prostap treatment?

A: Hair loss is documented in regulatory product information as an adverse reaction to Prostap, particularly in women. According to official product information, this effect may occur occasionally, affecting up to 1 in 100 people. It is not generally defined as a 'very common' side effect.

Q: Does Prostap affect sex drive in men or women?

A: Regulatory documents indicate that in men, a loss of interest in sexual intercourse (decreased libido) is listed as a very common side effect. Decreased libido is also a documented side effect in women.

Q: Can Prostap cause issues with sleep or insomnia?

A: Trouble sleeping and insomnia are documented as adverse reactions to the active ingredient in Prostap, indicating sleep disturbances may occur during treatment.

Q: Are the listed side effects of Prostap typically different for men and women?

A: Yes, official regulatory documents separate the side effects of Prostap into different sections for men and women. While common reactions like hot flashes occur in both, some effects are sex-specific, such as testicular atrophy in men or vaginal dryness in women.

Q: Does taking Prostap make you infertile permanently?

A: The drug’s intended action is a temporary suppression of the hormonal axis, and its effects are generally considered reversible. Official labeling indicates that normal menstrual cycles usually return after treatment stops for women. However, the overall effect on long-term fertility is not guaranteed, and the official label notes that caution is advised regarding this outcome.

Q: When do the side effects from Prostap usually start and stop?

A: At the beginning of treatment, patients may experience a temporary worsening of symptoms, known as the 'flare' effect, which subsides after the first few days. Other hormone-related side effects, such as hot flashes and joint pain, typically persist for the duration of the treatment until the hormone levels normalize after the medication is stopped.

Q: How long after starting Prostap can I generally expect to notice a difference in symptoms?

A: The time frame for noticeable symptom changes depends on the condition being treated. Studies indicate that for men, testosterone levels typically reach the suppressed range needed for treatment within two to four weeks of starting. Symptom relief for women's conditions is observed later, often after the first month of therapy or following the completion of the course.

Q: What is the usual total length of treatment with Prostap for conditions like uterine fibroids?

A: Official regulatory prescribing information recommends that the duration of therapy for uterine fibroids be limited to three months. This time limit is established to help minimize the risk of decreased bone mineral density associated with prolonged hormonal suppression.

Q: Do you need to stop Prostap treatment gradually, or is it usually stopped suddenly?

A: Regulatory documents describe treatment as limited to a specific total period (e.g., six months for endometriosis) and then discontinued. The official product information does not describe a gradual tapering process for stopping the medication.

Q: Is it described as safe to drink alcohol in moderation while on Prostap treatment?

A: The official labeling does not provide specific information regarding the consumption of alcohol in moderation. However, it lists chronic alcohol use as a major risk factor that may increase the potential for bone mineral density loss, which is a known side effect of Prostap.

Q: Can people with diabetes typically use Prostap?

A: Individuals with diabetes can generally use Prostap, but official product information describes the need for caution. Diabetic patients may require more frequent monitoring of blood glucose levels during treatment, as the medication can potentially affect glucose tolerance or aggravate pre-existing diabetes.

Q: Is Prostap generally suitable for people who have pre-existing heart conditions?

A: Official labeling states that the presence of pre-existing heart problems must be disclosed, as the medication may increase the risk of developing certain heart problems and requires monitoring throughout the course of treatment.

Q: Can Prostap be used by people with a history of depression or anxiety?

A: Regulatory information indicates that patients with a history of depression or anxiety require close monitoring while using Prostap. Official safety information notes an increased risk of new or worsening depression (which may be severe) in patients receiving GnRH agonists.

Q: Where can a patient find the official regulatory information about Prostap?

A: Patients can find the official document, typically known as the Patient Information Leaflet (PIL) or Package Leaflet, from their country’s medicine regulatory authority (such as the MHRA, HPRA, or resources like the FDA’s MedlinePlus). These documents contain complete, authoritative information about the drug.

Q: Why is Prostap sometimes described in high-level terms as a form of 'chemical castration'?

A: This term refers to the drug's effect of achieving a significant, controlled suppression of sex hormone production (testosterone and estrogen). The official pharmacological description is pharmacological hypophysectomy (suppression of the pituitary gland), which is the chemical mechanism that produces effects consistent with the term.

Q: Is Prostap considered a cure for the medical conditions it treats?

A: No, official documents describe Prostap as a treatment intended for the management of the conditions it addresses, such as prostate cancer and endometriosis. For benign conditions like uterine fibroids, symptoms will generally return after the therapy is stopped.

Q: Who is generally described as not eligible to receive Prostap in official information?

A: The drug is typically contraindicated (should not be used) if a patient has a known hypersensitivity to the drug or related hormones. It is also contraindicated for use during pregnancy or breastfeeding, and in women with undiagnosed abnormal vaginal bleeding.

How to Store and Dispose of Prostap

Official Storage Requirements

Prostap (leuprorelin acetate) must be stored strictly according to regulatory labeling to maintain its integrity.

Condition	Requirement (Regulatory Standard)
Temperature	Store at room temperature, not exceeding 25 C.
Prohibitions	Do not refrigerate or freeze.
Protection	Keep in the original container to protect from light.
Child Safety	Store out of the sight and reach of children.

Handling and Disposal

Prostap is a powder and solvent that must be reconstituted and used immediately before injection, as the suspension settles quickly. All unused medicine and waste materials must be disposed of according to local regulations. Used syringes and needles must be placed immediately into a suitable sharps container.